Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company's lead program is focused on the treatment of Friedreich's ataxia and discovery efforts are ongoing in other degenerative diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/24/20 | $45,000,000 | Series A |
Cormorant Asset Management Quan Capital SR One  WestRiver Group | undisclosed |
